Adjuvant therapy for renal cell carcinoma

Current Oncology Reports

Volumn 10, Issue 3, 2008, Pages 245-252

  Haas, Naomi B ^a   Uzzo, Robert ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; EPITHELIAL CELL ADHESION MOLECULE; GELSOLIN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY G250; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN P53; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VIMENTIN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG MEGADOSE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; MONOTHERAPY; NEPHRECTOMY; NOMOGRAM; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SURGICAL APPROACH; ADJUVANT CHEMOTHERAPY; IMMUNOTHERAPY; KIDNEY TUMOR; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 58149115366     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0037-4     Document Type: Review

References (67)

1. Kovacs G, Akhtar M, Beckwith BJ, et al.: The Heidelberg classification of renal cell tumours. J Pathol 1997, 183:131-133.
2. Gettman MT, Blute ML, Spotts B, et al.: Pathologic staging of renal cell carcinoma: Significance of tumor classification with the 1997 TNM staging system. Cancer 2001, 91:354-361.
3. Tsui KH, Shvarts O, Smith RB, et al.: Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000, 163:1090-1095.
4. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
5. Lam JS, Shvarts O, LeNpert JT, et al.: Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005, 173:1853-1862.
6. Frank I, Blute ML, Cheville JC, et al.: A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 2003, 170:2225-2232.
7. Moinzadeh A, Gill IS, Finelli A, et al.: Laparoscopic partial nephrectomy: 3-year followup. J Urol 2006, 175:459-462.
8. Hefez KS, Fergany AF, Novick AC: Nephron sparing surgery for localized renal cell carcinoma: Impact of tumor size on patient survival, tumor recurrence, and TNM staging. J Urol 1999, 162:1930-1933.
9. Gill IS, RemerOEM, Hasan WA, et al.: Renal cryoablation: outcome at 3 years. J Urol 2005, 173:1903-1907.
10. Frank I, Blute ML, Leibovich BC, et al.: Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005, 173:1889-1892.
11. Blom JH, van Poppel H, Marechal JM, et al.: Radical nephrectomy with and without lymph node dissection: Preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 1999, 36:570-575.
12. Eble JN, Sauter G, Epstein JI, Sesterhenn IA: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: International Agency for Research on Cancer Press; 2004, reprinted 2006.
13. Amin MB, Tamboli P, Javidan J, et al.: Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol 2002, 26:281-291.
14. Cheville JC, Lohse CM, Zincke H, et al.: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003, 27:612-624.
15. Ficarra V, Prayer-Galetti T, Novella G, et al.: Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol 2003, 43:663-669.
16. Patard JJ, Leray E, Rioux-Leclercq N, et al.: Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol 2005, 23:2763-2771.
17. Kim HL, Seligson D, Liu X, et al.: Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005, 173:1496-1501.
18. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway. Clin Cancer Res 2003, 9:4641-4652.
19. Leppert JT, Lam JS, Pantuck AJ, et al.: Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int 2005, 96:281-285.
20. Bui MH, Seligson D, Han KR, et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 2003, 9:802-811.
21. Shvarts O, Seligson D, Lam J, et al.: P53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma J Urol 2005, 173:725-728.
22. Yaycioglu O, Roberts WW, Chan T, et al.: Prognostic assessment of nonmetastatic renal cell carcinoma: A clinically based model. Urology 2001, 58:141-145.
23. Cindolo L, de la Taille A, Messina G, et al.: A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 2003, 92:901-905.
24. Zisman A, Pantuck AJ, Dorey F, et al.: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649-1657.
25. Zisman A, Pantuck AJ, Wieder J, et al.: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002, 20:4559-4566.
26. Patard JJ, Kim HL, Lam JS, et al.: Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An international multicenter study. J Clin Oncol 2004, 22:3316-3322.
27. Kattan MW, Reuter V, Motzer RJ, et al.: A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001, 166:63-67.
28. Sorbellini M, Kattan MW, Snyder ME, et al.: A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005, 173:48-51.
29. Frank I, Blute ML, Cheville JC, et al.: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol 2002, 168:2395-2400.
30. Ficarra V, Martignoni G, Lohse C, et al.: External validation of the Mayo Clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol 2006, 175:1235-1239.
31. Bukowski RM, Negrier S, Elson P: Prognostic factors in patients with advanced renal cell carcinoma: Development of an international kidney cancer working group. Clin Cancer Res 2004, 10(Pt 2):6310S-6314S.
32. Kjaer M, Iversen P, Hvidt V, et al.: A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 1987, 21:285-289.
33. Kjaer M, Frederiksen PL, Engelholm SA: Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987, 13:665-672.
34. Pizzocaro G, Piva L, Di Fronzo G, et al.: Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 1987, 138:1379-1381.
35. Atzpodien J, Schmitt E, Gertenbach U, et al.: Adjuvant treatment with interleukin-2 and interferon-alpha2a based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005, 92:843-846.
36. Galligioni E, Quaia M, Merlo A, et al.: Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guerin: Five-year results of a prospective randomized study. Cancer 1996, 77:2560-2566.
37. Messing EM, Manola J, Wilding G, et al.: Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003, 21:1214-1222.
38. Clark JI, Atkins MB, Urba WJ, et al.: Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial. J Clin Oncol 2003, 21:3133-3140.
39. Pizzocaro G, Piva L, Colavita M, et al.: Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study. J Clin Oncol 2001, 19:425-431.
40. Avigan DE, George DJ, Kantoff PW, et al.: Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumorderived cells in patients with stage IV renal cell carcinoma [ASCO abstract]. J Clin Oncol 2004, 22(14S Suppl): 2526.
41. Vieweg J, Fannull J: Tumor vaccines: from gene therapy to dendritic cells - the emerging frontier. Urol Clin North Am 2003, 30:633-643.
42. Bleumer I, de Mulder PH, Mulders PF: The role of adjuvant therapy in non-metastatic RCC. Can J Urol 2006, 13(Suppl 2):57-62.
43. Jocham D, Richter A, Hoffman L, et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomized controlled trial. Lancet 2004, 363:594-599.
44. Albers MW, Williams RT, Brown EJ, et al.: FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. J Biol Chem 1993, 268:22825-22829.
45. Brown EJ, Albers MW, Shin TB, et al.: A mammalian protein targeted by G1-arresting rapamycin receptor complex. Nature 1994, 369:756-758.
46. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al.: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006, 66:5549-5554.
47. Atkins MB, Hidalgo M, Stadler WM, et al.: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909-918.
48. Motzer RJ, Bacik J, Schwartz LH, et al.: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004, 22:454-463.
49. Hudes G, Carducci M, Tomczak P et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Temsirolimus, interferon alfa, or both for advanced renalcell carcinoma. N Engl J Med 2007, 356:2271-2281.
50. Mendel DB, Laird AD, Xin X, et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
51. O'Farrell AM, Abrams TJ, Yuen HA, et al.: SU 11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597.
52. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
53. Wilhelm SM, Carter C, Tang L, et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
54. Escudier B, Eisen T, Stadler W, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
55. Ratain MJ, Eisen T, Stadler WM, et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:2505-2512.
56. Szczylik C, Demkow T, Staehler M, et al.: Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):5025.
57. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
58. Escudier B, Koralewski P, Pluzanska A, et al.: A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/ interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):3.
59. Lam JS, Leppert JT, Belldegrun AS, Figlin RA: Adjuvant therapy of renal cell carcinoma: Patient selection and therapeutic options. BJU INT 2005, 96:483-488.
60. Liao SY, Aurelio ON, Jan K, et al.: Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997, 57:2827-2831.
61. Sokoloff MH, Daneshmand S, Ryan CW: Current clinical trials in renal cell carcinoma. Urol Oncol 2005, 23:289-292.
62. Eastern Cooperative Oncology Group website. http://www.ecog.org. Accessed November 2007.
63. ClinicalTrials.gov website. http://www.cancer.gov/clinicaltrials. Accessed November 2007.
64. Leibovich BC, Han K, Bui MHT, et al.: Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. Cancer 2003, 98:2566-2575.
65. Sunitinib Investigator' Brochure. New York, NY: Pfizer Inc.; 2004.
66. Shah A, Lathia C, Heininger K, et al.: (eds): Sorafenib Investigator's Brochure, version 5. West Haven, CT: Bayer Corporation; 2004.
67. Dancey JE: Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 2006, 5:1065-1073.